Niels Jessen

Delaying time to first nocturnal void may have beneficial effects on reducing blood glucose levels

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Delaying time to first nocturnal void may have beneficial effects on reducing blood glucose levels. / Juul, Kristian Vinter; Jessen, Niels; Bliwise, Donald L; van der Meulen, Egbert; Nørgaard, Jens Peter.

I: Endocrine, Bind 53, Nr. 3, 09.2016, s. 722-9.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Juul, KV, Jessen, N, Bliwise, DL, van der Meulen, E & Nørgaard, JP 2016, 'Delaying time to first nocturnal void may have beneficial effects on reducing blood glucose levels', Endocrine, bind 53, nr. 3, s. 722-9. https://doi.org/10.1007/s12020-016-0920-y

APA

Juul, K. V., Jessen, N., Bliwise, D. L., van der Meulen, E., & Nørgaard, J. P. (2016). Delaying time to first nocturnal void may have beneficial effects on reducing blood glucose levels. Endocrine, 53(3), 722-9. https://doi.org/10.1007/s12020-016-0920-y

CBE

MLA

Vancouver

Author

Juul, Kristian Vinter ; Jessen, Niels ; Bliwise, Donald L ; van der Meulen, Egbert ; Nørgaard, Jens Peter. / Delaying time to first nocturnal void may have beneficial effects on reducing blood glucose levels. I: Endocrine. 2016 ; Bind 53, Nr. 3. s. 722-9.

Bibtex

@article{d50b03bfd1cb4f4a8ab7caedf37453c8,
title = "Delaying time to first nocturnal void may have beneficial effects on reducing blood glucose levels",
abstract = "Experimental studies disrupting sleep and epidemiologic studies of short sleep durations indicate the importance of deeper and longer sleep for cardiometabolic health. We examined the potential beneficial effects of lengthening the first uninterrupted sleep period (FUSP) on blood glucose. Long-term data (≥3 months of treatment) were derived from three clinical trials, testing low-dose (10-100 µg) melt formulations of desmopressin in 841 male and female nocturia patients (90 % of which had nocturnal polyuria). We performed post hoc multiple regression with non-fasting blood glucose as dependent variable and the following potential covariates/factors: time-averaged change of FUSP since baseline, age, gender, race, ethnicity, baseline glucose, baseline weight, change in weight, patient metabolic status (normal, metabolic syndrome, type II diabetes), dose, follow-up interval, and time of random glucose sampling. Increases in FUSP resulted in statistically significant reductions in blood glucose (p = 0.0131), even after controlling for all remaining covariates. Per hour increase in time to first void was associated with glucose decreases of 1.6 mg/dL. This association was more pronounced in patients with increased baseline glucose levels (test of baseline glucose by FUSP change interaction: p < 0.0001). Next to FUSP change, other statistically significant confounding factors/covariates also associated with glucose changes were gender, ethnicity, metabolic subgroup, and baseline glucose. These analyses indicate that delaying time to first void may have beneficial effects on reducing blood glucose in nocturia patients. These data are among the first to suggest that improving sleep may have salutary effects on a cardiometabolic measure.",
keywords = "Aged, Antidiuretic Agents, Blood Glucose, Deamino Arginine Vasopressin, Diabetes Mellitus, Type 2, Female, Humans, Male, Metabolic Syndrome X, Middle Aged, Nocturia, Sleep, Treatment Outcome, Urination, Journal Article",
author = "Juul, {Kristian Vinter} and Niels Jessen and Bliwise, {Donald L} and {van der Meulen}, Egbert and N{\o}rgaard, {Jens Peter}",
year = "2016",
month = sep,
doi = "10.1007/s12020-016-0920-y",
language = "English",
volume = "53",
pages = "722--9",
journal = "Endocrine",
issn = "1355-008X",
publisher = "Humana Press, Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Delaying time to first nocturnal void may have beneficial effects on reducing blood glucose levels

AU - Juul, Kristian Vinter

AU - Jessen, Niels

AU - Bliwise, Donald L

AU - van der Meulen, Egbert

AU - Nørgaard, Jens Peter

PY - 2016/9

Y1 - 2016/9

N2 - Experimental studies disrupting sleep and epidemiologic studies of short sleep durations indicate the importance of deeper and longer sleep for cardiometabolic health. We examined the potential beneficial effects of lengthening the first uninterrupted sleep period (FUSP) on blood glucose. Long-term data (≥3 months of treatment) were derived from three clinical trials, testing low-dose (10-100 µg) melt formulations of desmopressin in 841 male and female nocturia patients (90 % of which had nocturnal polyuria). We performed post hoc multiple regression with non-fasting blood glucose as dependent variable and the following potential covariates/factors: time-averaged change of FUSP since baseline, age, gender, race, ethnicity, baseline glucose, baseline weight, change in weight, patient metabolic status (normal, metabolic syndrome, type II diabetes), dose, follow-up interval, and time of random glucose sampling. Increases in FUSP resulted in statistically significant reductions in blood glucose (p = 0.0131), even after controlling for all remaining covariates. Per hour increase in time to first void was associated with glucose decreases of 1.6 mg/dL. This association was more pronounced in patients with increased baseline glucose levels (test of baseline glucose by FUSP change interaction: p < 0.0001). Next to FUSP change, other statistically significant confounding factors/covariates also associated with glucose changes were gender, ethnicity, metabolic subgroup, and baseline glucose. These analyses indicate that delaying time to first void may have beneficial effects on reducing blood glucose in nocturia patients. These data are among the first to suggest that improving sleep may have salutary effects on a cardiometabolic measure.

AB - Experimental studies disrupting sleep and epidemiologic studies of short sleep durations indicate the importance of deeper and longer sleep for cardiometabolic health. We examined the potential beneficial effects of lengthening the first uninterrupted sleep period (FUSP) on blood glucose. Long-term data (≥3 months of treatment) were derived from three clinical trials, testing low-dose (10-100 µg) melt formulations of desmopressin in 841 male and female nocturia patients (90 % of which had nocturnal polyuria). We performed post hoc multiple regression with non-fasting blood glucose as dependent variable and the following potential covariates/factors: time-averaged change of FUSP since baseline, age, gender, race, ethnicity, baseline glucose, baseline weight, change in weight, patient metabolic status (normal, metabolic syndrome, type II diabetes), dose, follow-up interval, and time of random glucose sampling. Increases in FUSP resulted in statistically significant reductions in blood glucose (p = 0.0131), even after controlling for all remaining covariates. Per hour increase in time to first void was associated with glucose decreases of 1.6 mg/dL. This association was more pronounced in patients with increased baseline glucose levels (test of baseline glucose by FUSP change interaction: p < 0.0001). Next to FUSP change, other statistically significant confounding factors/covariates also associated with glucose changes were gender, ethnicity, metabolic subgroup, and baseline glucose. These analyses indicate that delaying time to first void may have beneficial effects on reducing blood glucose in nocturia patients. These data are among the first to suggest that improving sleep may have salutary effects on a cardiometabolic measure.

KW - Aged

KW - Antidiuretic Agents

KW - Blood Glucose

KW - Deamino Arginine Vasopressin

KW - Diabetes Mellitus, Type 2

KW - Female

KW - Humans

KW - Male

KW - Metabolic Syndrome X

KW - Middle Aged

KW - Nocturia

KW - Sleep

KW - Treatment Outcome

KW - Urination

KW - Journal Article

U2 - 10.1007/s12020-016-0920-y

DO - 10.1007/s12020-016-0920-y

M3 - Journal article

C2 - 27003433

VL - 53

SP - 722

EP - 729

JO - Endocrine

JF - Endocrine

SN - 1355-008X

IS - 3

ER -